CDK2 is an attractive therapeutic target as a single agent in CCNE1-amplified cancers as cell lines and xenograft models harboring the amplification fail to proliferate after knockdown or catalytic inhibition of CDK2 (54). This evidence concerns the gene CDK2 and cancer.